Research Committee Meetings Sample Clauses

Research Committee Meetings. During the term of the Phase 1 Development Program, the Research Committee shall meet quarterly or as otherwise agreed by the parties, and thereafter as necessary to oversee, review and coordinate the Development Program, but no less than annually, at such locations as the parties agree. Decisions of the Research Committee shall be by unanimous vote of the members.
Sample 1Sample 2
AutoNDA by SimpleDocs
Research Committee Meetings. Meetings of the Research Committee shall be held at intervals of three months, on an alternating basis, at BAVARIAN NORDIC's facilities in Copenhagen, Denmark and at EPIMMUNE's facilities in San Diego, California or at such other times and locations as determined by the Research Committee; provided that such meetings may be held by videoconference or teleconference as mutually agreed by the Parties. The initial meeting shall be held at BAVARIAN NORDIC's facilities as promptly as possible following the date hereof. Minutes of each meeting shall be prepared in duplicate and approved by the Research Committee and the approved minutes shall be signed and retained by each Program Liaison. At subsequent meetings, the members, among other things, shall report on the Research and Development Program activities undertaken since the prior meeting, exchange ideas and data regarding the Program Vaccine(s), exchange information about the patent status of the Program Vaccine(s), update the Research and Development Program as may be appropriate and discuss and resolve all other matters relevant to the activities of the Research and Development Program. BAVARIAN NORDIC and EPIMMUNE shall bear their respective expenses in attending the meetings of the Research Committee.
Sample 1
Research Committee Meetings. Progress Reports ------------------------------------------------ Composition of the Research Committee. For ArQule: D.L. Xxxxxx, XxD J.C. Xxxxx Xx. XxX (ArQule teamleader) R.A. Xxxxxxx Xxx Solvay: C.C. Xxxxx, XxD U. Prouschofe, PhD J. vxx Xxxxxx, XxD (Solvay teamleader) The Research Committee will meet quarterly to adapt and further define the research plan for the next 6 months and to discuss progress over the past 3 months. Chemical themes to be included in the Directed Array program and priority within the Research program will be decided upon by Solvay in consultation with ArQule. ArQule will provide Solvay with all relevant information to ArQule's best knowledge to enable sound decision making. Performance objectives, with respect to timing and number of compounds/number of themes, will be mutually defined by the Research Committee. Progress will be discussed at least once per month (by video or telephone conference) on basis of a written monthly progress report. The monthly progress report will be prepared by ArQule and will be sent to each of the Solvay Research Committee members in time for receipt at least 7 days prior to the progress discussion. The monthly progress report will contain any (updated) listing of the Arqule employees fully or partly involved in the Solvay Research program. With the extent of involvement indicated, in addition to adequate information with respect to status and progress of the running activities. The Research Committee aims for an open and highly interactive collaboration with the best scientific technical input from both sides. In addition to the Research Committee members, other ArQule or Solvay employees may be involved in part of the discussion upon agreement of the Research Committee team leaders. The term for the research plan outlined below starts at the effective closure date of the Research Development and license agreement and ends at June 30, 1996. The first quarter ArQule will have provided the equivalence of 30 months FTE capacity. The program outlined below for the first quarter is definitive and will be executed as agreed. Deviation will need the prior written approval of both the ArQule and the Solvay teamleaders.
Sample 1

Related to Research Committee Meetings

  • Committee Meetings Subject to Article 19.3(1) and unless the directors otherwise provide in the resolution appointing the committee or in any subsequent resolution, with respect to a committee appointed under Articles 19.1 or 19.2:

  • Research Committee 2.2.1 Establishment and Functions of the RC. -------------------------------------

  • Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

  • Advisory Committee (a) The Partnership shall have a committee (the “Advisory Committee”) consisting of Fund Investors or their representatives or designees selected by the Managing General Partner; provided that no member of the Advisory Committee shall be an Affiliate of the Managing General Partner (or a designee or representative thereof). The Managing General Partner will meet with the Advisory Committee at least semi-annually to consult on various matters concerning the Partnership, including financial statements and appraisals, the status of existing investments and such other matters as the Managing General Partner may determine or any member of the Advisory Committee may reasonably propose.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • JSC Meetings The JSC will meet at least [**], or more or less frequently as mutually agreed by the Parties, at such times as may be agreed to by the Parties. The JSC will determine its meeting locations, and whether to conduct a meeting in-person, by teleconference, or videoconference. Each Party is responsible for all costs and expenses incurred by it in connection with its participation in the meetings of the JSC. Each Party shall have the right to call a special meeting of the JSC at any time as necessary or desirable to address disputes or other matters within the scope of the JSC’s responsibilities by providing the other Parties with written notice to that effect. The JSC Chairs shall schedule and convene such special JSC meeting as soon as practicable following such notice. Each Party may, from time-to-time and with prior written notice to the JSC members of the other Parties, invite Project Team members and/or others of its employees, consultants or agents to attend relevant portions of a JSC meeting as necessary. The Sponsoring Party shall notify the other Parties in writing in the event that it wishes to invite a Third Party to attend a JSC meeting. Any such notice shall be provided at least [**] business days prior to the relevant JSC meeting and shall identify the relevant Third Party and briefly describe the reasons that the Sponsoring Party wishes to include the Third Party in the meeting. The attendance and participation of such Third Party shall be subject to the prior written consent of the Parties receiving such notice (such consent not to be unreasonably withheld). Any such consent granted by a Party shall be conditioned upon the consultant or contractor being bound by a written confidentiality and non-use agreement that is reasonably acceptable to the consenting Party. In the event the Sponsoring Party requires the attendance of such Third Party at subsequent JSC meetings, approval shall not be required for any Third Party who was previously approved by the other Parties and remains bound by an appropriate written confidentiality and non-use agreement at the time of the Project Team meeting, provided that the Sponsoring Party gives the other Parties prior notice of such attendance and the other Parties do not revoke their consent. The Parties’ respective JSC Chairs (as defined below) shall be responsible for ensuring compliance with the foregoing.

  • Operating Committee 7.01 To coordinate the operation of their respective generating, transmission and substation facilities, in order that the advantages to be derived hereunder may be realized by the parties hereto to the fullest practicable extent, the parties shall establish a committee of authorized representatives to be known as the Operating Committee. Each of the parties shall designate in writing delivered to the other party, the person who is to act as its representative on said committee (and the person or persons who may serve as alternates whenever such representative is unable to act). Each of such representatives and alternates shall be persons familiar with the generating, transmission, and substation facilities of the system of the party he represents, and each shall be fully authorized (1) to cooperate with the other representative (or alternates) and (2) to determine and agree from time to time, in accordance with this agreement and with any other relevant agreements then in effect between the parties, upon the following:

Time is Money Join Law Insider Premium to draft better contracts faster.